New York, United States
Atommap, founded in 2023, is at the forefront of innovation in the Biopharma and Biotechnology sectors. With its slogan, "We invent molecules to better health and life," the company emphasizes its dedication to advancing health through cutting-edge science and technology.
The company specializes in the invention of therapeutic molecules, leveraging a combination of quantum physics, artificial intelligence, and computation-driven design to achieve atomic precision. This innovative approach places Atommap as a unique player poised to deliver significant advancements in medical treatments.
Headquartered in the United States, Atommap recently secured a $7.08M Seed Round investment on November 13, 2023, demonstrating strong investor confidence in its potential. While investor names weren't disclosed, this seed funding is critical in propelling the company's early-stage development.
